MK-1654
Total Payments
$3.5M
Transactions
452
Doctors
7
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $526,670 | 106 | 2 |
| 2019 | $577,387 | 170 | 0 |
| 2018 | $1.4M | 165 | 5 |
| 2017 | $969,577 | 11 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.5M | 414 | 99.7% |
| Travel and Lodging | $5,206 | 12 | 0.2% |
| Consulting Fee | $4,538 | 5 | 0.1% |
| Food and Beverage | $1,202 | 21 | 0.0% |
Payments by Type
Research
$3.5M
414 transactions
General
$10,945
38 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Single Rising Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics andPharmacodynamics of MK-1654 in Healthy Subjects | Merck Sharp & Dohme Corporation | $2.6M | 0 |
| A Double-blind, Randomized, Placebo-controlled, Single Ascending Dose Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-1654 in Pre-Term and Full-Term Infants | Merck Sharp & Dohme Corporation | $796,051 | 0 |
| A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants | Merck Sharp & Dohme Corporation | $93,650 | 0 |
| Burden of readmission following RSV hospitalization | Merck Sharp & Dohme Corporation | $10,216 | 0 |
Top Doctors Receiving Payments for MK-1654
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Lincoln, NE | $3.5M | 414 |
| , MD | Pediatric Infectious Diseases | Columbus, OH | $4,038 | 4 |
| , M.D | Neonatal-Perinatal Medicine | Honolulu, HI | $1,879 | 8 |
| , MD | Adolescent Medicine | Galveston, TX | $1,272 | 7 |
| , M.D | Pediatric Emergency Medicine | San Antonio, TX | $1,271 | 6 |
| , M.D | Pediatrics | Charleston, SC | $1,003 | 6 |
| , MD | Neonatal-Perinatal Medicine | Washington, DC | $982.89 | 6 |
| , MD | Internal Medicine | Philadelphia, PA | $500.00 | 1 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $3.5M
- Total Doctors 7
- Transactions 452
About MK-1654
MK-1654 is a drug associated with $3.5M in payments to 7 healthcare providers, recorded across 452 transactions in the CMS Open Payments database. The primary manufacturer is Merck Sharp & Dohme Corporation.
Payment data is available from 2017 to 2020. In 2020, $526,670 was paid across 106 transactions to 2 doctors.
The most common payment nature for MK-1654 is "Unspecified" ($3.5M, 99.7% of total).
MK-1654 is associated with 4 research studies, including "A Single Rising Dose Clinical Trial to Study the Safety, Tolerability, Pharmacokinetics andPharmacodynamics of MK-1654 in Healthy Subjects" ($2.6M).